Under the new partnership, Abcam will provide its recombinant monoclonal antibody development technologies and expertise to enhance Nautilus' reagent research and development activities, according to the companies. A long-term supply relationship has also been established.

Initially, the partnership will focus on the collaborative development of affinity binding reagents for use on the Nautilus proteomic analysis system. The relationship will expand to large-scale manufacturing and the supply of reagents for commercialization, the companies said.

Abcam to purchase BioVision for $340M
Custom antibody developer Abcam plans to purchase biotechnology firm BioVision for $340 million.

Abcam opens new U.S.-based manufacturing facility
Abcam has opened a new 100,000-sq-ft facility in Waltham, MA, to serve as a hub for its research and development and commercial activities in the region.

Nautilus Biotechnology to merge with SPAC
Nautilus Biotechnology, a next-generation proteomics company, has entered into a definitive merger agreement with Arya Sciences Acquisition, a special...

Cancer Research UK, Abcam partner on cancer antibodies
Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used...

Nautilus to bring proteomics platform to market
Nautilus Biotechnology announced that it has raised $76 million to develop a single-molecule sensitivity proteomics platform. The funding efforts...